A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)

NCT07450001 | Not Yet Recruiting Phase 1

• 1 other identifier: GenSci134-202
• Study Type: interventional
• Target: 128
• Locations: 1 country
• Sites: 1

Brief Summary

This study comprises two phases: Phase Ib and Phase II. Phase Ib is a multicenter, randomized, open-label, active-controlled, single-dose, dose-escalation to assess safety, tolerability, PK/PD profile, and immunogenicity of GenSci134 in children with GHD. Phase II is a multicenter, randomized, open-label, active-controlled, multiple-dose, parallel-group study to assess the efficacy and safety of multiple subcutaneous doses of GenSci134 at different levels versus Norditropin® in children with GHD. It will also evaluate PK/PD profile and immunogenicity to support dose selection for Phase III.

Conditions

Pediatric Growth Hormone Deficiency

Keywords

GenSci134; PGHD

Outcome Measures

Primary Outcomes (2)

• Phase Ib: Treatment Emergent Adverse Events （TEAEs）

  From the first dose to Day 35

• Phase II: Annualized height velocity (AHV) at Week 24 of treatment

  24 weeks

Secondary Outcomes (13)

• Phase Ib: Areas under the drug concentration-time curve (AUC0-t, AUC0-∞) of GenSci134

  From Day 1 to Day 29

• Phase Ib: Time to maximum concentration (Tmax) of GenSci134

  From Day 1 to Day 29

• Phase Ib: Maximum concentration (Cmax) of GenSci134

  From Day 1 to Day 29

• Phase Ib: Half-life (t1/2) of GenSci134

  From Day 1 to Day 29

• Phase Ib: Serum level of IGF-1 and IGFBP-3 and their changes from baseline.

  From Day 1 to Day 29

Study Arms (2)

Dose Level 1~ Dose Level 6

EXPERIMENTAL

dose level 1、dose level 2、dose level 3、dose level 4、 dose level 5、dose level 6

Drug: GenSci134 Injection

Recombinant Human Growth Hormone Injection (Norditropin®)

ACTIVE COMPARATOR

Active control group

Drug: Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)

Interventions

GenSci134 Injection DRUG

only one dose of GenSci134 to be given, subcutaneous , 6 dose levels will be assigned.

Also known as: GenSci134

Dose Level 1~ Dose Level 6

Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®) DRUG

multiple doses of Norditropin® FlexPro® quaque die (QD) for 28 consecutive days by subcutaneous injections.

Also known as: Norditropin®

Recombinant Human Growth Hormone Injection (Norditropin®)

Eligibility Criteria

• Age: 3 Years - 12 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Informed consent of parent or legal representative of participant and child assent, as age appropriate must be obtained before any study-related activities.
• At the time of signing the Informed consent form (ICF), the following conditions must be met:
• Phase Ib:
• Girls: age ≥3and ≤11 years, breast development at Tanner stage 1, body weight ≥16 kg; Boys: age ≥3 and ≤12 years, testis volume \<4 mL, body weight ≥16 kg.
• Phase II:
• Girls: age ≥3 and ≤9 years, breast development at Tanner stage 1; Boys: age ≥3 and ≤10 years, testis volume \<4 mL.
• BMI within the range of ±2 SD of the mean BMI for age and sex at screening
• Height is at least 2 SD below the mean HT for age and sex (HT SDS ≤ -2.0) at screening according to the normal pediatric population standards
• Diagnosis of GHD confirmed by two different GH stimulation tests performed at screening or within 12 months prior to screening.
• No prior exposure to GH or IGF-1therapy.
• Absence of intracranial tumor, as confirmed by MRI or CT. Images or scans obtained within 1 year prior to screening can be used as screening data if accompanied by a medical evaluation and conclusion.
• AHV \<5 cm/year at screening (Phase II only);
• BA \< CA at screening (Phase II only);
• IGF-1 SDS ≤ -1.0 at screening (Phase II only).

You may not qualify if:

• Presence of one or more pituitary hormone deficiencies in addition to growth hormone deficiency.
• Any suspected or known disease likely to affect growth, or any clinically significant abnormality that would preclude the accurate assessment of standing height (Phase II only), including but not limited to:
• Turner syndrome
• Noonan syndrome
• Laron Syndrome
• Other genetic syndromes with short stature that are caused by chromosomal abnormalities or gene mutations, including but not limited to Prader-Willi syndrome, abnormal SHOX-1 gene analysis, or GH receptor deficiency.
• Born small for gestational age
• Growth retardation due to malnutrition
• Growth retardation due to hypothyroidism.
• Short stature with any other clearly identified etiology.
• Congenital abnormalities causing skeletal abnormalities, or claudication (Phase II only).
• Significant spinal abnormalities (Phase II only).
• Epiphyseal closure (Phase II only).
• Abnormal liver function, renal function, or coagulation profile
• Current or prior history of any malignant disease; or a family history of malignancy.

Sponsors & Collaborators

• Changchun GeneScience Pharmaceutical Co., Ltd.: lead

Study Sites (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

Wuhan, Hubei, 430000, China

Location

MeSH Terms

Interventions

Human Growth Hormone

Intervention Hierarchy (Ancestors)

Growth Hormone; Pituitary Hormones, Anterior; Pituitary Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins

Central Study Contacts

Jinbo Li

CONTACT

+86 15001322766; lijinbo@genscigroup.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 12, 2026
• First Posted: March 4, 2026
• Study Start: March 6, 2026
• Primary Completion (Estimated): July 18, 2028
• Study Completion (Estimated): December 31, 2028
• Last Updated: March 4, 2026

Record last verified: 2026-02

Locations

CN (1)